Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study (MIDAS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Bayer
Information provided by (Responsible Party):
Bayer Identifier:
First received: October 10, 2013
Last updated: November 14, 2016
Last verified: November 2016
The study is designed as non interventional to observe the continuation rate and the patient satisfaction in women who have a LNG-IUS (Levonorgestrel releasing Intrauterine system) inserted for contraception over the period of 12 months under real life condition in India.The study will begin after the study approval by ethics committee.All Indian women aged between 18-49 years who are initiating LNG IUS therapy for contraception will be included in study after taking the informed consent.Patients will be observed for upto 12 months.The study involves general examination of patients, collection of data like medical history, previous contraceptive use,concomitant medication etc.The study is planned to enroll 600 subjects from multiple study centers spread across India. The study data will be analyzed with appropriate statistical methods.

Condition Intervention
Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Percentage continuation rate of LNG IUS at end of observation period. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cumulative discontinuation rate for pregnancy [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Cumulative discontinuation rate for other medical reasons [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Cumulative discontinuation rate for non-medical reasons [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Mean percentage of women with amenorrhea [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Mean percent of women with spotting, inter-menstrual bleeding [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Distribution of contraceptive usage patterns [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    contraceptive usage patterns included:birth-spacing, long term contraception, postpartum contraception, post-abortion contraception, switch from other method, contraception for other medical reasons like heart disease, etc

  • Incidence rate of drug-related adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 600
Study Start Date: November 2015
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1
BAY 86-5028; Levonorgestrel- Intra Uterine System
Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)
Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study subjects will be enrolled from multiple sites like women's hospitals, tertiary care institutes, Family planning clinics and gynaecological consulting centres.

Inclusion Criteria:

  • Subject aged between 18-49 years who are initiating LNG IUS therapy for contraception.
  • Subject willing to provide informed consent and comply with study procedure.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01961375

Contact: Bayer Clinical Trials Contact

Many Locations, India
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT01961375     History of Changes
Other Study ID Numbers: 16199  MA1210IN 
Study First Received: October 10, 2013
Last Updated: November 14, 2016
Health Authority: India: Drugs Controller General of India

Additional relevant MeSH terms:
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral processed this record on December 09, 2016